A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice
- 1 March 2001
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 37 (5), 620-628
- https://doi.org/10.1016/s0959-8049(00)00437-8
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Cancer mortality in Europe, 1990–1994, and an overview of trends from 1955 to 1994European Journal Of Cancer, 1999
- Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238International Journal of Cancer, 1999
- Insulin secretion is inhibited by subtype five somatostatin receptor in the mouseSurgery, 1998
- Somatostatin receptor expression in lung cancerEuropean Journal Of Cancer, 1994
- Somatostatin and the immune and haematopoetic system; a reviewEuropean Journal of Clinical Investigation, 1994
- Somatostatin receptor subtype gene expression in human and rodent tumorsLife Sciences, 1993
- Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combinationBreast Cancer Research and Treatment, 1992
- Recombinant Toxins for Cancer TreatmentScience, 1991
- Somatostatin receptors are present in small‐cell but not in non‐small‐cell primary lung carcinomas: Relationship to EGF‐receptorsInternational Journal of Cancer, 1990
- Improved silver technique for showing nucleolar organiser regions in paraffin wax sections.Journal of Clinical Pathology, 1989